 The FDA has signed off Nuvation Bio Incs NYSE: NUVB investigational new drug IND application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET family that epigenetically regulates proteins that control tumor growth and differentiation. 